Vericel to Report Third-Quarter 2023 Financial Results on November 8, 2023

Rhea-AI Summary

Vericel Corporation (NASDAQ:VCEL) will report its third-quarter 2023 financial results on November 8, 2023. The company's management will host a conference call and webcast to discuss the results and business highlights.

Positive

• Vericel Corporation will announce its third-quarter financial results, potentially providing insights into the company's performance and future prospects.

Negative

• No negative takes identified.

CAMBRIDGE, Mass., Oct. 25, 2023 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that it will report its third-quarter 2023 financial results on Wednesday, November 8, 2023. Vericel’s management will host a conference call and webcast at 8:30 a.m. (ET) to discuss its financial results and business highlights.

The live webcast can be accessed on the Investor Relations section of the Vericel website at http://investors.vcel.com/events-presentations. Please visit the site at least 15 minutes prior to the scheduled start time in order to register and download the required audio software, if necessary. Presentation slides for the conference call will be available on the webcast and on the Investor Relations section of the Vericel website. 

To participate by telephone, please register here to receive dial-in details and your personal passcode. A replay of the webcast will be available on the Vericel website until November 8, 2024.

About Vericel Corporation

Vericel is a leader in advanced therapies for sports medicine and severe burn care. The Company manufactures and markets two cell therapy products and one specialty biologic product in the United States. MACI® (autologous cultured chondrocytes on porcine collagen membrane) is an autologous cellularized scaffold product indicated for the repair of symptomatic, single or multiple full-thickness cartilage defects of the knee with or without bone involvement in adults. Epicel® (cultured epidermal autografts) is a permanent skin replacement for the treatment of patients with deep dermal or full thickness burns greater than or equal to 30% of total body surface area. Vericel also holds an exclusive license for North American rights to NexoBrid® (anacaulase-bcdb), a biological orphan product containing proteolytic enzymes, which is indicated for the removal of eschar in adults with deep partial-thickness and/or full-thickness burns. For more information, please visit www.vcel.com.

Epicel® and MACI® are registered trademarks of Vericel Corporation. NexoBrid® is a registered trademark of MediWound Ltd. and is used under license to Vericel Corporation. © 2023 Vericel Corporation. All rights reserved.

Investor Contact:

Eric Burns

ir@vcel.com

+1 (734) 418-4411

Media Contact:

Julie Downs

media@vcel.com

FAQ

When will Vericel Corporation report its third-quarter 2023 financial results?

Vericel Corporation will report its third-quarter 2023 financial results on November 8, 2023.

How can I access the conference call and webcast?

The conference call and webcast can be accessed on the Investor Relations section of the Vericel website at http://investors.vcel.com/events-presentations.

Will presentation slides be available for the conference call?

Yes, presentation slides for the conference call will be available on the webcast and on the Investor Relations section of the Vericel website.

How long will the webcast replay be available?

The webcast replay will be available on the Vericel website until November 8, 2024.